TWI312779B - - Google Patents

Download PDF

Info

Publication number
TWI312779B
TWI312779B TW090133464A TW90133464A TWI312779B TW I312779 B TWI312779 B TW I312779B TW 090133464 A TW090133464 A TW 090133464A TW 90133464 A TW90133464 A TW 90133464A TW I312779 B TWI312779 B TW I312779B
Authority
TW
Taiwan
Prior art keywords
group
mmol
compound
fluoro
acid
Prior art date
Application number
TW090133464A
Other languages
English (en)
Chinese (zh)
Inventor
Nakayama Atsushi
Machinaga Nobuo
Yoneda Yoshiyuki
Sugimoto Yuichi
Chiba Jun
Watanabe Toshiyuki
Iimura Shin
Original Assignee
Daiichi Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Seiyaku Co filed Critical Daiichi Seiyaku Co
Application granted granted Critical
Publication of TWI312779B publication Critical patent/TWI312779B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/42—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Indole Compounds (AREA)
TW090133464A 2000-12-28 2001-12-28 TWI312779B (esLanguage)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000402890 2000-12-28
JP2001149923 2001-05-18

Publications (1)

Publication Number Publication Date
TWI312779B true TWI312779B (esLanguage) 2009-08-01

Family

ID=26607210

Family Applications (1)

Application Number Title Priority Date Filing Date
TW090133464A TWI312779B (esLanguage) 2000-12-28 2001-12-28

Country Status (16)

Country Link
US (1) US7157487B2 (esLanguage)
EP (1) EP1346982B1 (esLanguage)
JP (1) JP4212358B2 (esLanguage)
KR (1) KR100884877B1 (esLanguage)
CN (1) CN100471838C (esLanguage)
AR (1) AR035218A1 (esLanguage)
AT (1) ATE524441T1 (esLanguage)
AU (1) AU2002219555B2 (esLanguage)
BR (1) BR0116608A (esLanguage)
CA (1) CA2430978C (esLanguage)
IL (1) IL156064A0 (esLanguage)
MX (1) MXPA03005838A (esLanguage)
NO (1) NO326014B1 (esLanguage)
RU (1) RU2290403C2 (esLanguage)
TW (1) TWI312779B (esLanguage)
WO (1) WO2002053534A1 (esLanguage)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0031315D0 (en) * 2000-12-21 2001-02-07 Glaxo Group Ltd Indole derivatives
WO2003082272A1 (en) * 2002-03-29 2003-10-09 Chiron Corporation Substituted benzazoles and use thereof as raf kinase inhibitors
DK1549638T3 (da) * 2002-10-03 2008-01-21 Hoffmann La Roche Indol-3-carboxamider som glucokinase (GK) aktivatorer
US20070066577A1 (en) * 2003-04-03 2007-03-22 Hea Young Park Choo Benzoxazole derivative or analogue thereof for inhibiting 5-lipoxygenase and pharmaceutical composition containing same
WO2004099136A1 (ja) * 2003-05-09 2004-11-18 Daiichi Pharmaceutical Co., Ltd. ピロリジン誘導体の製造方法
EP1479675A1 (en) * 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Indazole-derivatives as factor Xa inhibitors
US7691894B2 (en) 2003-07-24 2010-04-06 Daiichi Pharmaceutical Co., Ltd. Cyclohexanecarboxylic acid compound
US6984652B2 (en) 2003-09-05 2006-01-10 Warner-Lambert Company Llc Gyrase inhibitors
WO2005063678A1 (ja) * 2003-12-26 2005-07-14 Daiichi Pharmaceutical Co., Ltd フェニル酢酸誘導体の製造方法
JPWO2005066124A1 (ja) * 2003-12-26 2007-12-20 第一三共株式会社 ピロリジン誘導体の製造法
WO2005090329A1 (en) * 2004-03-24 2005-09-29 Jerini Ag New compounds for the inhibition of angiogenesis and use of thereof
JP2005350417A (ja) * 2004-06-11 2005-12-22 Dai Ichi Seiyaku Co Ltd 還元的エーテル化法を用いたピロリジン誘導体の製造法
TW200610754A (en) * 2004-06-14 2006-04-01 Daiichi Seiyaku Co Vla-4 inhibitor
EP1771169A1 (en) 2004-07-14 2007-04-11 PTC Therapeutics, Inc. Methods for treating hepatitis c
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
CA2578636A1 (en) 2004-07-22 2006-02-23 Ptc Therapeutics, Inc. Thienopyridines for treating hepatitis c
JP2006056830A (ja) * 2004-08-20 2006-03-02 Dai Ichi Seiyaku Co Ltd ２−アリールアミノベンゾオキサゾール誘導体
EP1831225A2 (en) 2004-11-19 2007-09-12 The Regents of the University of California Anti-inflammatory pyrazolopyrimidines
BRPI0615248A2 (pt) * 2005-08-26 2009-07-14 Shionogi & Co derivado tendo atividade agonista de ppar
WO2007069635A1 (ja) * 2005-12-13 2007-06-21 Daiichi Sankyo Company, Limited Ｖｌａ－４阻害薬
EP2004654B1 (en) 2006-04-04 2013-05-22 The Regents of the University of California Pyrazolopyrimidine derivatives for use as kinase antagonists
DE102006021878A1 (de) * 2006-05-11 2007-11-15 Sanofi-Aventis Phenylamino-benzoxazol substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US7858645B2 (en) * 2006-11-01 2010-12-28 Hoffmann-La Roche Inc. Indazole derivatives
WO2009046448A1 (en) 2007-10-04 2009-04-09 Intellikine, Inc. Chemical entities and therapeutic uses thereof
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
MX2010007419A (es) 2008-01-04 2010-11-12 Intellikine Inc Ciertas entidades quimicas, composiciones y metodos.
WO2009114874A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Benzothiazole kinase inhibitors and methods of use
JP5547099B2 (ja) * 2008-03-14 2014-07-09 インテリカイン， エルエルシー キナーゼ阻害剤および使用方法
US20110224223A1 (en) * 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
US9096611B2 (en) * 2008-07-08 2015-08-04 Intellikine Llc Kinase inhibitors and methods of use
JP5731978B2 (ja) 2008-09-26 2015-06-10 インテリカイン， エルエルシー 複素環キナーゼ阻害剤
AU2009305669A1 (en) 2008-10-16 2010-04-22 The Regents Of The University Of California Fused ring heteroaryl kinase inhibitors
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
SI3354650T1 (sl) 2008-12-19 2022-06-30 Vertex Pharmaceuticals Incorporated Spojine, uporabne kot zaviralci ATR kinaze
WO2010098866A1 (en) 2009-02-27 2010-09-02 Supergen, Inc. Cyclopentathiophene/cyclohexathiophene dna methyltransferase inhibitors
CA2760791C (en) 2009-05-07 2017-06-20 Intellikine, Inc. Heterocyclic compounds and uses thereof
EP2440057A4 (en) 2009-06-09 2012-12-05 California Capital Equity Llc TRIAZINE DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS
US8877924B2 (en) 2009-06-09 2014-11-04 NantBio Inc. Benzyl substituted triazine derivatives and their therapeutical applications
US9345699B2 (en) 2009-06-09 2016-05-24 Nantbioscience, Inc. Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling
US20120258093A1 (en) 2009-08-20 2012-10-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy
WO2011047384A2 (en) 2009-10-16 2011-04-21 The Regents Of The University Of California Methods of inhibiting ire1
WO2011056652A1 (en) 2009-10-28 2011-05-12 Newlink Genetics Imidazole derivatives as ido inhibitors
CN103002738A (zh) 2010-05-21 2013-03-27 英特利凯恩有限责任公司 用于激酶调节的化学化合物、组合物和方法
JP2013545749A (ja) 2010-11-10 2013-12-26 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環化合物及びその使用
US8809349B2 (en) 2011-01-10 2014-08-19 Infinity Pharmaceuticals, Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
CN103491962B (zh) 2011-02-23 2016-10-12 因特利凯有限责任公司 激酶抑制剂的组合及其用途
TWI565709B (zh) 2011-07-19 2017-01-11 英菲尼提製藥股份有限公司 雜環化合物及其用途
US8969363B2 (en) 2011-07-19 2015-03-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
SG11201400310WA (en) 2011-08-29 2014-06-27 Infinity Pharmaceuticals Inc Heterocyclic compounds and uses thereof
EP2751112B1 (en) 2011-09-02 2019-10-09 The Regents of The University of California Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
CA2886240A1 (en) 2012-09-26 2014-04-03 The Regents Of The University Of California Modulation of ire1
MX386085B (es) 2012-11-01 2025-03-18 Infinity Pharmaceuticals Inc Tratamiento de canceres utilizando moduladores de las isoformas de pi3 cinasa
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
CN105793255B (zh) 2013-10-04 2018-11-16 无限药品股份有限公司 杂环化合物及其用途
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MX382033B (es) 2014-03-19 2025-03-13 Infinity Pharmaceuticals Inc Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma.
US20150320755A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
BR112017009513A2 (pt) * 2014-11-06 2018-02-06 Basf Se utilização de um composto heterobicíclico, utilização dos compostos i, compostos, composição agrícola ou veterinária, método para o combate ou controle de pragas, método para a proteção de culturas e sementes
CR20170594A (es) 2015-06-09 2018-04-27 Abbvie Inc Moduladores de receptor nuclear
US10160761B2 (en) 2015-09-14 2018-12-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
RU2754507C2 (ru) 2016-06-24 2021-09-02 Инфинити Фармасьютикалз, Инк. Комбинированная терапия
LT3873884T (lt) 2018-10-30 2025-03-10 Gilead Sciences, Inc. 3-(chinolin-8-il)-1,4-dihidropirido[3,4-d]pirimidin-2,4-diono dariniai kaip alfa4beta7 integrino inhibitoriai, skirti uždegiminių ligų gydymui
EP3873897B1 (en) 2018-10-30 2024-08-14 Gilead Sciences, Inc. N-benzoyl-phenylalanine derivatives as alpha4beta7 integrin inhibitors for treating inflammatory diseases
PL3873900T3 (pl) 2018-10-30 2025-06-02 Gilead Sciences, Inc. Imidazo[1,2-a]pirydynowe pochodne jako inhibitory integryny alpha4beta7 do leczenia chorób zapalnych
KR102659859B1 (ko) 2018-10-30 2024-04-25 길리애드 사이언시즈, 인코포레이티드 알파4β7 인테그린의 억제를 위한 화합물
EP4013499A1 (en) 2019-08-14 2022-06-22 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
JP7620649B2 (ja) 2020-06-10 2025-01-23 アリゴス セラピューティクス インコーポレイテッド コロナウイルス、ピコルナウイルス及びノロウイルス感染を治療するための抗ウイルス化合物
EP4284947A1 (en) 2021-01-29 2023-12-06 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods of assessing the risk of developing progressive multifocal leukoencephalopathy in patients treated with vla-4 antagonists
CA3224494A1 (en) 2021-07-09 2023-01-12 Koen Vandyck Anti-viral compounds
US12065428B2 (en) 2021-09-17 2024-08-20 Aligos Therapeutics, Inc. Anti-viral compounds

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204261B1 (en) 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
DE2500157C2 (de) * 1975-01-03 1983-09-15 Hoechst Ag, 6230 Frankfurt N-Acyl-4-(2-aminoäthyl)-benzoesäuren, deren Salze und Ester, Verfahren zu deren Herstellung und deren Verwendung
DE2706977A1 (de) * 1977-02-18 1978-08-24 Hoechst Ag Benzoesaeuren und deren derivate sowie verfahren zu ihrer herstellung
US4184658A (en) * 1978-02-13 1980-01-22 General Electric Company Cushion mount for prime mover
DE3063878D1 (en) 1979-07-13 1983-07-28 Thomae Gmbh Dr K Derivatives of carboxylic acids, their preparation and medicaments containing them
JPS60181081A (ja) 1984-02-29 1985-09-14 Kaken Pharmaceut Co Ltd 新規ビスベンゾフラニルケトン誘導体
JPH04112868A (ja) 1990-09-03 1992-04-14 Otsuka Pharmaceut Co Ltd 置換ヘテロ環を有するフェニルカルボン酸誘導体
JPH0543574A (ja) 1991-08-13 1993-02-23 Wakamoto Pharmaceut Co Ltd ヘテロ環置換テトラゾール−１−酢酸誘導体
FR2694295B1 (fr) * 1992-07-28 1994-09-02 Adir Nouveaux peptides dérivés de trifluoromethylcetones, leur procéde de préparation et les compositions pharmaceutiques qui les contiennent.
US5821231A (en) 1993-12-06 1998-10-13 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using same
ES2103181B1 (es) * 1994-08-01 1998-04-01 Menarini Lab Amidas naftalenicas con accion antagonista de los leucotrienos.
GB9408936D0 (en) * 1994-05-05 1994-06-22 Cancer Res Inst Anti-cancer compounds
US6306840B1 (en) 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
CA2225666A1 (en) * 1995-06-30 1997-01-23 Smithkline Beecham Corporation Use of stat 5 sh2 domain specific compounds to enhance erythropoiesis
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
ES2271971T3 (es) 1996-07-25 2007-04-16 Biogen Idec Ma Inc. Inhibidores de la adhesion celular.
JP2000516958A (ja) 1996-08-26 2000-12-19 ジェネティックス・インスチチュート・インコーポレーテッド ホスホリパーゼ酵素の阻害剤
DE19647381A1 (de) 1996-11-15 1998-05-20 Hoechst Ag Neue Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
ID21956A (id) * 1996-11-22 1999-08-19 Elan Pharm Inc Asam n-(aril dan atau heteroarilasetil) amino ester, komposisi farmasi yang mengandungnya, dan metoda untuk menghambat pelepasan betha-amiloid peptida dan atau sintesanya dengan menggunakan senyawa tersebut
US6117901A (en) * 1996-11-22 2000-09-12 Athena Neurosciences, Inc. N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for use
IL136584A (en) 1997-12-23 2005-03-20 Aventis Pharma Ltd SUBSTITUTED beta-ALANINES, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND USES THEREOF
ID26123A (id) * 1998-02-25 2000-11-23 Genetics Inst Penghambat-penghambat phospholipase a2
PL198189B1 (pl) * 1998-05-28 2008-06-30 Biogen Idec Ma (R)-N-{[4-{[(2-metylofenyloamino)-karbonylo]amino}fenylo]acetylo}-L-prolilo-3-metylo]-ß-alanina, jej zastosowanie i kompozycja farmaceutyczna ją zawierająca
AU758567B2 (en) 1998-06-08 2003-03-27 Ajinomoto Co., Inc. Benzamidine derivative
EA004792B1 (ru) 1998-06-30 2004-08-26 Пфайзер Продактс Инк. Непептидные ингибиторы vla-4-зависимого клеточного связывания, полезные в лечении воспалительных, аутоиммунных и респираторных заболеваний
EP1133484A2 (en) * 1998-07-23 2001-09-19 AstraZeneca AB Heterocyclic derivatives and their use as integrin inhibitors
GB9916374D0 (en) 1998-07-23 1999-09-15 Zeneca Ltd Chemical compounds
AU754557B2 (en) 1998-08-26 2002-11-21 Aventis Pharma Limited Aza-bicycles which modulate the inhibition of cell adhesion
GB9821199D0 (en) * 1998-09-30 1998-11-25 Glaxo Group Ltd Chemical compounds
US6207700B1 (en) * 1999-01-07 2001-03-27 Vanderbilt University Amide derivatives for antiangiogenic and/or antitumorigenic use
ATE325105T1 (de) 1999-02-16 2006-06-15 Aventis Pharma Ltd Bicyclische verbindungen und ihre verwendung als integrinrezeptorliganden
JP2000344666A (ja) * 1999-04-01 2000-12-12 Sankyo Co Ltd 糖及び脂質代謝改善剤
DE60017389T2 (de) 1999-04-12 2006-03-02 Aventis Pharma Ltd., West Malling Substituierte bicyclische heteroaryl-verbindungen als integrin antagonisten
ES2226832T3 (es) 1999-05-05 2005-04-01 Aventis Pharma Limited Pirrolidinas sustituidas como inhibidores de la adhesion celular.
DE60026514T2 (de) * 1999-05-05 2006-11-09 Merck & Co., Inc. Neue prolinverbindungen als mikrobizide mittel
WO2000068213A1 (en) 1999-05-05 2000-11-16 Aventis Pharma Limited Substituted bicyclic compounds
WO2000068223A1 (en) 1999-05-05 2000-11-16 Aventis Pharma Limited Ureas and their use as cell adhesion modulators
US6756378B2 (en) * 1999-06-30 2004-06-29 Pharmacopeia Drug Discovery, Inc. VLA-4 inhibitor compounds
JP2003503350A (ja) 1999-06-30 2003-01-28 第一製薬株式会社 Ｖｌａ−４インヒビター化合物
WO2001012186A1 (en) 1999-08-13 2001-02-22 Biogen, Inc. Cell adhesion inhibitors
AU2155001A (en) 1999-11-10 2001-06-06 Aventis Pharma Deutschland Gmbh N-acylpyrrolidin-2-ylalkylbenzamidine derivatives as inhibitors of factor xa
IL149758A0 (en) * 1999-12-28 2002-11-10 Pfizer Prod Inc Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases
GB0001346D0 (en) 2000-01-21 2000-03-08 Astrazeneca Uk Ltd Chemical compounds
DE10006453A1 (de) 2000-02-14 2001-08-16 Bayer Ag Piperidylcarbonsäuren als Integrinantagonisten
GB0004686D0 (en) 2000-02-28 2000-04-19 Aventis Pharma Ltd Chemical compounds
WO2001064640A1 (en) 2000-03-01 2001-09-07 Aventis Pharma Limited 2,3-dihydro-1h-indolinyl-alkanoic acids as cell adhesion inhibitors
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
CA2414311C (en) 2000-07-19 2008-01-08 F. Hoffmann-La Roche Ag Pyrrolidine derivatives as inhibitors of endothelin-converting enzyme
GB2377933A (en) 2001-07-06 2003-01-29 Bayer Ag Succinic acid derivatives useful as integrin antagonists

Also Published As

Publication number Publication date
HK1081545A1 (zh) 2006-05-19
KR100884877B1 (ko) 2009-02-23
NO20032994L (no) 2003-08-27
US7157487B2 (en) 2007-01-02
MXPA03005838A (es) 2003-09-10
EP1346982B1 (en) 2011-09-14
JPWO2002053534A1 (ja) 2004-04-30
CN100471838C (zh) 2009-03-25
CA2430978A1 (en) 2002-07-11
CN1483024A (zh) 2004-03-17
BR0116608A (pt) 2004-06-29
EP1346982A1 (en) 2003-09-24
ATE524441T1 (de) 2011-09-15
RU2290403C2 (ru) 2006-12-27
NO326014B1 (no) 2008-09-01
CA2430978C (en) 2012-05-15
EP1346982A4 (en) 2005-08-10
RU2003123115A (ru) 2005-03-27
HK1060726A1 (zh) 2004-08-20
IL156064A0 (en) 2003-12-23
WO2002053534A1 (en) 2002-07-11
WO2002053534A8 (en) 2002-09-19
JP4212358B2 (ja) 2009-01-21
US20040110945A1 (en) 2004-06-10
KR20030067730A (ko) 2003-08-14
AU2002219555B2 (en) 2006-11-30
NO20032994D0 (no) 2003-06-27
AR035218A1 (es) 2004-05-05

Similar Documents

Publication Publication Date Title
TWI312779B (esLanguage)
AU2021381437B2 (en) Novel spiropyrrolidine derived antiviral agents
EP3728238B1 (en) Sulphonyl urea derivatives as nlrp3 inflammasome modulators
CA3199074A1 (en) Compounds and methods for the targeted degradation of androgen receptor protein
JP6399148B2 (ja) 血栓塞栓症の治療のための第ＸＩａ因子阻害剤としての置換ピロリジン
AU2014342338B2 (en) Aminoheteroaryl benzamides as kinase inhibitors
IL272527A (en) Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders
CN112218859A (zh) 蛋白水解调节剂及相关使用方法
WO2019177902A1 (en) Modulators of btk proteolysis and methods of use
JP2021531234A (ja) ヒトインテグリンα４β７のアンタゴニスト
JP2019537605A (ja) アルファｖインテグリン阻害剤としてのシクロブタン−およびアゼチジン−含有の単環およびスピロ環式化合物
TW201416362A (zh) １－（環烷基羰基）脯胺酸衍生物
JP2012176973A (ja) Ｈｃｖインヒビター
TW200404796A (en) Nitrogen-containing compound
JP2021519266A (ja) ３−ヒドロキシ−Ｎ−（３−（７Ｈ−ピロロ［２，３−ｄ］ピリミジン−４−イル）フェニル）ピロリジン−１−カルボキサミド誘導体
TW200924790A (en) Macrocyclic inhibitors of hepatitis C virus NS3 serine protease
JP6337750B2 (ja) 化合物
CN112566900A (zh) 免疫调节剂及其组合物和制备方法
JP4324221B2 (ja) Ｐｐａｒアゴニスト活性を有する誘導体
TWI258469B (en) Aryl-substituted alicyclic compounds and pharmaceutical composition containing the same
TW202342061A (zh) Ｌｏｎｐ１抑制劑、用途及方法
CN115197194A (zh) Zeste增强子同源物2抑制剂及其用途
CA2844865A1 (en) 3-pyridine carboxylic acid hydrazides as hdl-cholesterol raising agents
HK40039990A (en) Sulphonyl urea derivatives as nlrp3 inflammasome modulators
HK40039990B (en) Sulphonyl urea derivatives as nlrp3 inflammasome modulators

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees